PFE · Pfizer Inc · Financials
$28.59
-0.13 (-0.45%)
At close · Sep 30
Return incl. dividend (before tax)
Market Cap
$163.41B
Shares
5.70B
Volume · Sep 30
33.65M
Avg daily vol (3M)
37.77M
Income-statement, balance-sheet and cash-flow figures from SEC filings, plus a debt profile anchored in the latest 10-K and updated by each 10-Q and debt exhibit.
Revenue
$62.58B
-1.6%
FY2025
Net Income
$7.77B
-3.2%
FY2025
Gross Margin
74.33%
+2.4pp
FY2025
Diluted EPS
$1.36
-3.5%
FY2025
Operating Cash Flow
$11.7B
-8.2%
FY2025
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 | FY2012 | FY2011 | FY2010 | FY2009 | FY2008 | FY2007 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| $63.7B | $62.58B | $63.63BG | $59.55BG | $101.18B | $81.29BG | $41.65B | $40.91B | $40.83B | $52.55B | $52.82B | — | — | $51.58B | $54.66B | $61.04B | $65.17B | $49.27B | $48.3B | $48.42B | |
| — | — | — | — | — | — | — | — | — | — | — | — | — | -$1.01B | -$1.14B | -$1.23B | — | — | — | — | |
| $17.08B | $16.07B | $17.85B | $24.95B | $34.34B | $30.82B | $8.48B | $8.05B | $8.99B | $11.23B | $12.32B | $9.65B | $9.58B | $9.59B | $9.82B | $12.5B | $14.79B | $8.46B | $8.11B | $11.24B | |
| $46.61B | $46.51B | $45.78B | $34.6B | $66.83B | $50.47B | $33.17B | $32.85B | $31.84B | $41.32B | $40.5B | — | — | $42B | $44.84B | $48.54B | $50.38B | $40.81B | $40.18B | $37.18B | |
| — | 74.33% | 71.94% | 58.1% | 66.05% | 62.08% | 79.63% | 80.31% | 77.99% | 78.63% | 76.67% | — | — | 81.42% | 82.03% | 79.52% | 77.31% | 82.83% | 83.2% | 76.79% | |
| $11.05B | $10.44B | $10.82B | $10.68B | $11.43B | $10.36B | $8.71B | $8.39B | $7.76B | $7.68B | $7.89B | $7.69B | $8.39B | $6.68B | $7.48B | $8.68B | $9.48B | $7.82B | $7.95B | $8.09B | |
| $13.72B | $13.79B | $14.73B | $14.77B | $13.68B | $12.7B | $11.6B | $12.73B | $12.61B | $14.8B | $14.84B | $14.81B | $14.1B | $14.36B | $15.17B | $17.58B | $18.97B | $14.75B | $14.54B | $15.63B | |
| $5B | — | $5.3B | $4.7B | $3.6B | $3.7B | $3.4B | $4.5B | — | — | — | $3.8B | $4.1B | $4.8B | $5.3B | $5.7B | $5.5B | $2.88B | $2.67B | $3.13B | |
| $6.58B | $6.59B | $7.01B | $6.29B | $5.06B | $5.19B | $4.68B | $5.76B | $6.38B | $6.27B | $5.76B | $5.16B | $5.54B | $6.31B | $7.39B | $8.7B | $8.4B | $4.76B | $5.09B | $5.2B | |
| $1.01B | $1.09B | $1.99B | $1.97B | $882M | $741M | $535M | $227M | $796M | $30M | $1.06B | $811M | $170M | $1.04B | $1.43B | $2.12B | — | — | — | — | |
| $2.7B | $2.67B | $3.09B | $2.21B | $1.24B | $1.29B | $1.45B | $1.57B | $1.32B | $1.27B | $1.19B | $1.2B | $1.36B | $1.41B | $1.52B | $1.68B | $1.8B | $1.23B | $516M | — | |
| $532M | $603M | $545M | $1.62B | $251M | $36M | $73M | $225M | $333M | $391M | $470M | $471M | $425M | $403M | $382M | $456M | — | — | — | — | |
| -$9.61B | -$6.72B | -$4.39B | -$222M | -$1.06B | $4.88B | -$1.21B | -$3.5B | -$2.08B | -$1.42B | -$3.79B | -$2.86B | -$1.01B | $532M | -$4.02B | -$139M | $147M | -$62M | -$48M | — | |
| — | — | -$420M | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| — | — | — | — | — | — | — | — | — | — | — | $45M | $86M | — | — | — | — | — | — | — | |
| $4.21B | $7.52B | $8.02B | $1.06B | $34.73B | $24.31B | $7.04B | $11.32B | $3.59B | $12.31B | $8.35B | $8.97B | $12.24B | $15.72B | $11.24B | $11.48B | $9.47B | $10.67B | $9.69B | $9.28B | |
| -$164M | -$266M | -$28M | -$1.12B | $3.33B | $1.85B | $370M | $583M | -$266M | -$9.05B | $1.12B | $1.99B | $3.12B | $4.31B | $2.22B | $3.62B | $1.15B | $2.15B | $1.65B | $1.02B | |
| $4.33B | $7.77B | $8.03B | $2.12B | $31.37B | $21.98B | $9.16B | $16.03B | $11.15B | $21.31B | $7.22B | $6.96B | $9.14B | $22B | $14.57B | $10.01B | $8.26B | $8.64B | $8.1B | $8.14B | |
| — | 12.42% | 12.62% | 3.56% | 31.01% | 27.04% | 21.99% | 39.18% | 27.32% | 40.55% | 13.66% | — | — | 42.65% | 26.66% | 16.4% | 12.67% | 17.53% | 16.78% | 16.82% | |
| $35M | $41M | $31M | $39M | $35M | $45M | $36M | $29M | $36M | $47M | $31M | $26M | $32M | $69M | $28M | $40M | $31M | $8M | $23M | $42M | |
| $4.33B | $7.77B | $8.03B | $2.12B | $31.37B | $21.98B | $9.16B | $16.03B | $11.15B | $21.31B | $7.21B | $6.96B | $9.13B | $22B | $14.57B | $10.01B | $8.26B | $8.63B | $8.1B | — | |
| $5.55B | $7.54B | $8.15B | $2.46B | $28.97B | $21.39B | $9.64B | $15.91B | $9.2B | $23.02B | $5.7B | $4.76B | $5.09B | $24.66B | $12.75B | $9.32B | $4.27B | — | — | — | |
| USD/shares | $0.77 | $1.37 | $1.42 | $0.38 | $5.59 | $3.92 | $1.65 | $2.88 | $1.90 | $3.39 | $1.12 | $1.07 | $1.37 | $3.06 | $1.86 | $1.21 | $0.98 | $1.17 | $1.14 | $1.12 |
| USD/shares | $0.76 | $1.36 | $1.41G | $0.37G | $5.47 | $3.85G | $1.63 | $2.82 | $1.87 | $3.34 | $1.11 | $1.05 | $1.35 | $3.03 | $1.84 | $1.20 | $0.97 | $1.17 | $1.14 | $1.11 |
| shares | — | 5.68B | 5.66B | 5.64B | 5.61B | 5.6B | 5.56B | 5.57B | 5.87B | 6.29B | 6.42B | 6.51B | 6.69B | 7.18B | 7.84B | 8.24B | 8.47B | 7.39B | 7.09B | 7.29B |
| shares | — | 5.71B | 5.7B | 5.71B | 5.73B | 5.71B | 5.63B | 5.68B | 5.98B | 6.39B | 6.49B | 6.59B | 6.77B | 7.27B | 7.91B | 8.29B | 8.51B | 7.43B | 7.11B | 7.31B |
Italic rows are computed from reported lines — open a row's info icon for its formula. Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative. (G): the company's own guidance — a (G) column is a guided period not yet reported; a G marker shows how the reported figure landed against the guided range. Non-GAAP-basis guidance (*) is shown as stated and never judged against GAAP actuals.
Capital Returned to Shareholders
Cash spent on share repurchases and dividends per fiscal year, as reported on the cash-flow statement. Across FY2007–FY2024: $89.24B in buybacks.
Debt Profile
Completed filing coverage through Aug 4, 2026Annual debt figures are established from 10-K filings and updated by subsequent 10-Q and 8-K disclosures. Instrument balances are not summed into a company total unless the filing itself reports that total.
1 filing observation remains unmatched and is excluded from instrument histories.
Debt data is being processed. Please check back later.
1 filing has incomplete source or extraction coverage. Verified observations are shown; missing observations do not establish that debt was unchanged.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.
Valuation
EV/Revenue
3.54×
Peer median 6.93×
EV/EBIT
—
P/E (TTM)
37.72×
Peer median 35.60×
Peer medians compare against the 8 similar-size Drug Manufacturers - General companies (of 13 listed).
Valuation over time computed as of each quarter's filing date
Revenue Breakdown
Annual revenue as the company disaggregates it in its own XBRL filings. Years a component wasn't reported show a dash.
Share mode is each component's slice of the reported components that year — issuers rarely tag every revenue dollar, so slices need not sum to total revenue.
By Segment (USD)
| Component | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Biopharma Segment | $61,199,000,000 | $62,400,000,000 | $58,237,000,000 | $99,826,000,000 | $79,557,000,000 | $40,724,000,000 | $38,013,000,000 |
| Business Innovation Segment | — | — | $1,310,000,000 | $1,342,000,000 | $1,731,000,000 | $926,000,000 | $810,000,000 |
By Geography (USD)
| Component | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| United States | $37,078,000,000 | $38,691,000,000 | $28,145,000,000 | $43,317,000,000 | $29,746,000,000 | $21,455,000,000 | $20,326,000,000 | $20,119,000,000 |
| International Developed Markets | $16,188,000,000 | $16,057,000,000 | $20,910,000,000 | $40,534,000,000 | — | — | — | — |
| International Emerging Markets | $9,313,000,000 | $8,879,000,000 | $10,498,000,000 | $17,324,000,000 | — | — | — | — |
| Developed Europe | — | — | — | — | $18,336,000,000 | $7,788,000,000 | $7,729,000,000 | $7,997,000,000 |
| Developed Rest of World | — | — | — | — | $12,506,000,000 | $4,036,000,000 | $4,022,000,000 | $4,090,000,000 |
| Emerging Markets | — | — | — | — | $20,701,000,000 | $8,372,000,000 | $8,828,000,000 | $8,618,000,000 |
By Product & Service (USD)
| Component | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Product | $51,663,000,000 | $53,816,000,000 | $50,914,000,000 | $91,793,000,000 | — | — | — | — |
| Royalty | $1,650,000,000 | $1,423,000,000 | $1,058,000,000 | $845,000,000 | — | — | — | — |
| Pfizer Centre One | $1,338,000,000 | $1,146,000,000 | $1,272,000,000 | $1,342,000,000 | — | — | — | — |
| Pfizer Ignite | $41,000,000 | $82,000,000 | $44,000,000 | $7,000,000 | — | — | — | — |
| Paxlovid NDA Labeled US Strategic National Stockpile | — | $442,000,000 | — | — | — | — | — | — |
| Total Alliance Biopharmaceuticals | — | — | — | — | $7,652,000,000 | $5,418,000,000 | $4,648,000,000 | $3,838,000,000 |
| Total Biosimilars | — | — | — | — | $2,343,000,000 | $1,527,000,000 | $911,000,000 | $769,000,000 |
| Total Sterile Injectable Pharmaceuticals | — | — | — | — | $5,746,000,000 | $5,315,000,000 | $5,013,000,000 | $5,173,000,000 |